Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus NITROFURANTOIN MACROCRYSTALLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus NITROFURANTOIN MACROCRYSTALLINE.
COR-OTICIN vs NITROFURANTOIN MACROCRYSTALLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inhibit multiple bacterial enzymes involved in carbohydrate metabolism, including acetyl-CoA synthetase, and disrupt cell wall synthesis.
1-2 drops in each affected ear twice daily for 7 days.
100 mg orally twice daily for 5-7 days (uncomplicated UTI); 100 mg orally every 12 hours for 10-14 days (pyelonephritis: not first-line).
None Documented
None Documented
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Terminal half-life: 20-60 minutes (short, requires q6h dosing for therapeutic efficacy).
Renal (60-80% unchanged), fecal/biliary (5-10%)
Renal: 30-40% excreted unchanged in urine. Biliary/fecal: minimal; remainder metabolized or eliminated via other routes.
Category C
Category D/X
Topical Corticosteroid + Antibiotic
Antibiotic